EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma

Leonardo Gomes da Fonseca, Federico Piñero, Margarita Anders, Carla Bermudez, Ezequiel Demirdjian, Adriana Varón, Daniela Perez, Jorge Rodriguez, Oscar Beltrán, Ezequiel Ridruejo, Pablo Caballini, Alexandre Araujo und 8 weitere

Oncotarget · 2025

DOI: 10.18632/oncotarget.28721 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncotarget, 2025. Verfasst von Leonardo Gomes da Fonseca und 19 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedLatin AmericaProspective StudiesAdultIncidenceAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

adverse eventsimmunologyimmunotherapyliver cancerreal-world

Substanzen

BevacizumabatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Brazil.
  • Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Argentina.
  • Department of Hepatology, Hospital Alemán, Argentina.
  • Department of Hepatology and Liver Transplantation, Hospital Italiano de Buenos Aires, Argentina.
  • Department of Liver Transplantation, Sanatorio Sagrado Corazón, Argentina.
  • Department of Hepatology, Fundación Cardioinfantil, Colombia.

Zitieren

APA

da Fonseca, L. G., Piñero, F., Anders, M., Bermudez, C., Demirdjian, E., Varón, A., Perez, D., Rodriguez, J., Beltrán, O., Ridruejo, E., Caballini, P., Araujo, A., Florez, J. D. T., Marín, J. I., Villa, M., Orozco, F., Poniachik, J., Marciano, S., Bessone, F., & Mendizabal, M. (2025). Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.28721

Vancouver

da Fonseca LG, Piñero F, Anders M, Bermudez C, Demirdjian E, Varón A, et al. Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma. Oncotarget. 2025. doi:10.18632/oncotarget.28721

BibTeX
@article{daFonseca2025,
  author = {da Fonseca, Leonardo Gomes and Piñero, Federico and Anders, Margarita and Bermudez, Carla and Demirdjian, Ezequiel and Varón, Adriana and Perez, Daniela and Rodriguez, Jorge and Beltrán, Oscar and Ridruejo, Ezequiel and Caballini, Pablo and Araujo, Alexandre and Florez, Juan Diego Torres and Marín, Juan Ignacio and Villa, Marina and Orozco, Federico and Poniachik, Jaime and Marciano, Sebastián and Bessone, Fernando and Mendizabal, Manuel},
  title = {Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma},
  journal = {Oncotarget},
  year = {2025},
  doi = {10.18632/oncotarget.28721}
}
Kostenlos starten →